Now I have the favorability ratings. Let me produce the final consolidated review.

---

## Summary

This paper argues that molecular diffusion models fail because molecular data distributions have a "dense-concentrated structure" (DC-structure): narrow, sharply separated peaks corresponding to valid molecules, with large low-density gaps. The paper formalizes this notion, analyzes how small score-estimation errors can cause reverse trajectories to overshoot valid regions, and proposes DIST — a plug-in corrective method that filters intermediate samples via pilot evaluation at a chosen timestep, discarding batches likely to lead to invalid structures. Experiments across three backbone models (EDM, GeoLDM, RADM) on QM9 show consistent improvements (e.g., molecule stability from 82.0%→89.9% for EDM), and modest gains on GEOM-Drugs.

## Strengths

- **DC-structure is a useful conceptual lens, grounded in the paper's formalization (Definition 3.1, Sec. 3.1).** The characterization — molecular distributions as narrow peaks separated by low-density gaps where even small errors cause irreversible drift — provides an intuitive vocabulary for a known but underexplained failure mode. While the observation builds on prior work, the explicit formulation as a mixture-of-narrow-Gaussians with an overshoot condition (Eqs. 6–7) sharpens the discussion beyond what prior papers have offered.

- **Empirical results are consistently positive across diverse backbones on QM9, with substantial improvements.** Every backbone (EDM, GeoLDM, RADM) improves when augmented with DIST. The gains are non-trivial on key metrics — molecule stability for EDM rises from 82.0% to 89.9%, validity from 91.9% to 96.9% (Table 2). Standard deviations over three runs are reported. The improvements hold across GNN-based equivariant, Transformer-based non-equivariant, regular-space, and latent-space models, supporting the claim that the issue is not purely architectural.

- **The plug-in nature is practically valuable.** DIST does not require retraining or modifying backbone model weights (Sec. 4.1), using the officially released weights of each backbone unchanged. This means it can be applied to existing pre-trained molecular diffusion models directly, with no architectural changes.

## Weaknesses

### Fatal
None.

### Major

- **Efficiency claims are misleading because pilot computation is omitted from the accounting.** The paper advertises that DIST "reduces computational cost to nearly half the standard number of timesteps" (abstract, Sec. 4.3). The reported metric (e.g., 307 steps for the example in Sec. 4.3, and ~400–600 in Table 3) counts only the amortized cost of candidate generation from \(T\) to \(t\) plus the remaining steps from \(t\) to 0 *for accepted samples*. It omits the cost of running full reverse inference on pilot subsets — which is documented on line 176 ("runs a full reverse inference on a pilot subset") but never added to the total. The pilot runs are additional neural-network evaluations that standard 1000-step baselines do not incur. A pilot set of size 30 (the smallest in Table 4) performing \(t\) steps each would add thousands of function evaluations not reflected in the "average timesteps" metric. Without a transparent total-compute comparison that includes all pilot costs and discarded candidates, the efficiency advantage claimed in the abstract and conclusion is unsubstantiated. **This is a genuine evidential gap: the efficiency benefit may still be real, but the paper has not demonstrated it.**

- **The "theory" contribution is oversold.** Listed as a main contribution (line 28), the theoretical content consists of: (a) **Definition 3.1**, which is an assumption about molecular distributions (a Gaussian-mixture model with narrow, well-separated components) stated as a definition — no empirical evidence is given that molecules quantitatively satisfy this structure at any noise level; (b) **Equations 6–7**, which are algebraic consequences of plugging a specific score approximation (assuming \(z_t\) is exactly at the midpoint between two equally weighted isotropic Gaussians) into the reverse update — a plausible but highly specific scenario; (c) **Corollary 3.1** (TV-contraction), a standard property of any well-behaved Markov kernel (data processing inequality), not specific to molecules, diffusion, or DIST; (d) **Proposition 3.1**, an error bound whose explicit form is deferred to the appendix and depends on quantities not accessible during inference (true coverage \(\alpha(\tau)\), conditional discrepancies \(\text{TV}(q_{t,j}, p_{t,j})\)). The analysis provides a useful conceptual vocabulary and plausible intuition, but it is not a theory in any non-trivial sense — there are no testable predictions, no novel derived bounds with practical implications, and no quantitative insight that could guide method design beyond "filter out bad intermediate samples." The paper would be better served by presenting this as "analysis" or "a conceptual framework."

- **The method is underspecified in the main paper on essential operational details.** The pilot score \(s_j\), which is the **core** mechanism driving the correction, is listed only as vague alternatives: "e.g., round-trip residual, self-consistency, ensemble variance, or chemistry-based penalty" (lines 150–151), without stating which one is actually used in any experiment. These are fundamentally different quantities — a self-consistency check and a chemistry-based penalty operate on entirely different principles. Similarly, the threshold \(\tau\) and intermediate correction timestep \(t\) are not reported in the main paper, and the perturbation added for batch construction is described only as "sufficiently small" (line 176). While appendices (F, H) presumably contain these details, a reader cannot tell from the main text what DIST actually does. The single most important missing fact is **which pilot score was used** — this should be in the main paper.

### Minor

- **On GEOM-Drugs, the evidence for the core claim is weak.** The paper transparently states that molecule stability is near 0% for all methods and omits it (line 203, "following prior work"). However, this means that on the more challenging and realistic dataset, the central claim — that DIST "realigns inference trajectories toward a valid molecular distribution" — is supported only by ~1 percentage point atom-stability gains (e.g., RADM 85.0%→86.0%, Table 2). No method produces reliably stable molecules on GEOM-Drugs, so the paper's pitch about solving the structural validity problem is significantly qualified for this setting.

- **No experimental comparison with other corrective or resampling strategies.** The paper compares only against unaugmented backbone models and two older non-diffusion baselines (ENF 2021, G-SchNet 2019). It does not compare against classifier guidance, REPAINT-style resampling (Lugmayr et al., 2022), or simple rejection sampling (generate many molecules, keep only valid ones). Each of these is a natural alternative for improving validity, and the absence of such comparisons makes it difficult to assess whether DIST's specific mechanism adds value beyond simpler approaches.

- **The claim of being "the first to highlight" the concentrated nature of molecular distributions (line 27) is overstated.** Prior diffusion-based molecular generation works extensively discuss the difficulty of enforcing chemical validity under diffusion, which is the same underlying observation. This should be contextualized rather than presented as a novel discovery.

- **GEOM-Drugs results lack confidence intervals.** QM9 results include standard deviations over three runs. GEOM-Drugs results are reported as point estimates without variance, making it unclear whether the small improvements (~1 pp) are statistically significant.

### Trivial

- The non-diffusion baselines (ENF from 2021, G-SchNet from 2019) are several years old; more recent non-diffusion molecular generation methods are not compared, though the paper's contribution is orthogonal to this axis.

## Nice-to-Haves

- An ablation study in the main paper for the actual method-specific hyperparameters (threshold \(\tau\), intermediate timestep \(t\), perturbation intensity) rather than only pilot subset size (Table 4). The paper states these are in Appendix H.
- A simple rejection-sampling baseline (generate many molecules, select valid ones) would help contextualize the efficiency-quality trade-off achieved by DIST's more targeted filtering.

## Removed Points

These points are flagged to be removed; treat them with caution:
- **"The efficiency formula derivation is questionable"** (parallelization detail): The paper's formula \((T-t)/|B| + t\) under ideal parallelism is a standard accounting convention. The real issue (missing pilot costs) is already captured in the Major weakness above.
- **"Table 1 degradation is expected / known property"**: This is a correct observation but not a weakness — the paper uses Table 1 to motivate correction, which is reasonable.
- **"The score magnitude assumption is restrictive"**: This is a valid observation about the specificity of the theoretical derivation, already captured in the Major weakness about the theory being oversold.
- **"GEOM-Drugs is selective reporting"**: The paper transparently explains why molecule stability is omitted (line 203, "following prior work"). The retained version of this criticism is about the limited support for the core claim on large molecules, not about concealment.

## Novel Insights

None beyond the paper's own contributions. The reviewer's analysis does surface confirmations (e.g., Corollary 3.1 being a standard property) but does not add non-obvious observations absent from the paper.

## Suggestions

1. **Account for pilot costs transparently.** Report total neural network evaluations or total FLOPs including pilot runs, discarded candidates, and any overhead. The efficiency claim should be backed by a complete compute comparison, not "average timesteps for accepted batches."
2. **Specify the pilot score function in the main text.** State definitively which of the listed alternatives (round-trip residual, self-consistency, etc.) was used, and provide evidence that it correlates with validity.
3. **Scale back the "Theory" framing.** Present the analysis as a conceptual framework or mathematical intuition for why correction helps, rather than as a formal theory. This would better match what is actually provided.
4. **Include GEOM-Drugs molecule stability and confidence intervals.** Even if near 0% for all methods, reporting it transparently would strengthen the paper's credibility and clarify the limitations.
5. **Add a simple baseline comparison** (e.g., rejection sampling or classifier guidance) to contextualize DIST's specific advantage.

## Score and Decision

The core empirical contribution — a plug-in corrective method that consistently improves molecular diffusion model quality on QM9 — is solid and practically useful. The improvements are non-trivial and hold across multiple backbones. However, the paper overstates two things: the efficiency advantage (pilot costs are unaccounted for) and the theoretical contribution (the analysis is insightful but not a formal theory). The method is also underspecified in the main paper on its most critical design choice (the pilot score). On GEOM-Drugs, the improvements are modest and the core claim is only weakly supported. These issues are addressable in revision but are non-trivial. I recommend a borderline accept with a clear expectation that the efficiency accounting and theoretical framing be corrected before publication.

MY FINAL SCORE: <score>6</score>
MY FINAL DECISION: <decision>Accept</decision>